Your SlideShare is downloading. ×
Impact of Emerging Markets in Global Pharma 2013 and role of Top 12 Pharma
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Impact of Emerging Markets in Global Pharma 2013 and role of Top 12 Pharma

1,080
views

Published on

Global Pharmaceutical market grew 2% in 2013 although Developed and Emerging Markets played a very different role: …

Global Pharmaceutical market grew 2% in 2013 although Developed and Emerging Markets played a very different role:
While EM delivered 30 bn USD of additional revenues, DM reduced sales more than 8 bn USD
Within Developed Markets, EU dropped 16 bn USD (-7%) versus 2012 while USA, Canada, Japan and other APAC developed markets grew at an average of 2%
In Emerging Markets, BRIC contributed more than 80% to growth, meaning 25 bn USD, while rest of Pharmerging represented nearly 5 additional billion
Top 12 Pharmaceutical Companies represent 39% of Global Pharmaceutical Market in 2013 with much stronger position in Developed Markets (42,5%) than in Emerging Markets (27%)
In 2013 MS of Top 12 declined in both market segments, but while in DM decrease was 0,8%, in EM nearly doubled (-1,5%)
While more than 80% of Market Growth is delivered by Emerging Markets, Big Pharma is strongly losing MS on this Market Segment

Published in: Healthcare, Business

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,080
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
30
Comments
0
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Pharmaceutical Emerging Markets Impact on Global Pharmaceutical Market 2012-2013 Emergpharma Pannel Preliminary Results More information: www.emergpharma.com
  • 2. Global Pharmaceutical Market 2011-2013 (bn USD) 751.91 743.79 305.30 335.86 - 200.00 400.00 600.00 800.00 1,000.00 1,200.00 2012 2013 Developed Markets Emerging Markets +2% -1 % +10% Source: Emergpharma Pannel
  • 3. Emerging Markets (bn USD) 152.44 178.42 152.86 157.44 - 50.00 100.00 150.00 200.00 250.00 300.00 350.00 2012 2013 BRIC Other Emerging +3% +17% Source: Emergpharma Pannel
  • 4. Developed Markets(bn USD) 239.54 223.50 512.37 520.29 - 100.00 200.00 300.00 400.00 500.00 600.00 700.00 800.00 2012 2013 EU Rest of Dev. Markets -1% +2% -7% Source: Emergpharma Pannel
  • 5. Market Growth 2013 (bn USD by Segment) Global Market 2012 BRIC Rest of Emerging Developed Markets Global Market 2013 +25,3 +4,6 -8,1 Source: Emergpharma Pannel
  • 6. Top 12 Pharma in Global Market Novartis, Pfizer, Merck, Sanofi, GSK, Roche, Astra, J&J, Abbvie, Teva, Lilly and Boehringer Ingelheim 412.32 406.75 644.89 661.03 - 200.00 400.00 600.00 800.00 1,000.00 1,200.00 2012 2013 Top 12 Rest +3% -1% Source: Emergpharma Pannel
  • 7. Pharma Top 12 in Global, Developed and Emerging Markets 39.0% 38.1% 43.3% 42.5% 28.5% 27.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 2012 2013 MS Top 12 Global MS Top 12 Dev Markets MS Top 12 Emerging Markets Source: Emergpharma Pannel
  • 8. Market Growth Drivers 2013 25 8 4.6 -16 BRIC Non European Dev Markets Non BRIC Emerging Markets EU bn USD Source: Emergpharma Pannel
  • 9. Summary • Global Pharmaceutical market grew 2% in 2013 although Developed and Emerging Markets played a very different role • While EM delivered 30 bn USD of additional revenues, DM reduced sales more than 8 bn USD • Within Developed Markets, EU dropped 16 bn USD (-7%) versus 2012 while USA, Canada, Japan and other APAC developed markets grew at an average of 2% • In Emerging Markets, BRIC contributed more than 80% to growth, meaning 25 bn USD, while rest of Pharmerging represented nearly 5 additional billion • Top 12 Pharmaceutical Companies represent 39% of Global Pharmaceutical Market in 2013 with much stronger position in Developed Markets (42,5%) than in Emerging Markets (27%) • In 2013 MS of Top 12 declined in both market segments, but while in DM decrease was 0,8%, in EM nearly doubled (-1,5%) • While more than 80% of Market Growth is delivered by Emerging Markets, Big Pharma is strongly losing MS on this Market Segment Source: Emergpharma Pannel